Are GSK2118436 and GSK1120212 effective in melanoma cell lines harboring V600BRAF mutations different from the common V600EBRAF variant? / Ascierto, P; Gentilcore, G; Madonna, G; Assunta, E; Pirozzi, G; De Maio, E; Curvietto, M; Palmieri, G; Mozzillo, N; Legos, J. - In: EUROPEAN JOURNAL OF CANCER. - ISSN 0959-8049. - 47:(2011), pp. S11-S11.

Are GSK2118436 and GSK1120212 effective in melanoma cell lines harboring V600BRAF mutations different from the common V600EBRAF variant?

Ascierto P;
2011

2011
Are GSK2118436 and GSK1120212 effective in melanoma cell lines harboring V600BRAF mutations different from the common V600EBRAF variant? / Ascierto, P; Gentilcore, G; Madonna, G; Assunta, E; Pirozzi, G; De Maio, E; Curvietto, M; Palmieri, G; Mozzillo, N; Legos, J. - In: EUROPEAN JOURNAL OF CANCER. - ISSN 0959-8049. - 47:(2011), pp. S11-S11.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/1014163
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 1
social impact